



US008633309B2

(12) **United States Patent**  
**Ross et al.**

(10) **Patent No.:** **US 8,633,309 B2**  
(45) **Date of Patent:** **\*Jan. 21, 2014**

- (54) **NUCLEOSIDE PHOSPHORAMIDATES**
- (71) Applicant: **Gilead Pharmasset LLC**, Foster City, CA (US)
- (72) Inventors: **Bruce Ross**, El Granada, CA (US); **Michael Joseph Sofia**, Doylestown, PA (US); **Ganapati Reddy Pamulapati**, San Ramon, CA (US); **Suguna Rachakonda**, Twinsburg, OH (US); **Hai-Ren Zhang**, San Jose, CA (US); **Byoung-Kwon Chun**, Robbinsville, NJ (US); **Peiyuan Wang**, Totowa, NJ (US)
- (73) Assignee: **Gilead Pharmasset LLC**, Foster City, CA (US)
- (\* ) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.  
  
This patent is subject to a terminal disclaimer.
- (21) Appl. No.: **13/738,425**
- (22) Filed: **Jan. 10, 2013**
- (65) **Prior Publication Data**  
US 2013/0137654 A1 May 30, 2013

5,223,263 A	6/1993	Hostetler et al.
5,256,641 A	10/1993	Yatvin et al.
5,256,798 A	10/1993	Chou et al.
5,372,808 A	12/1994	Blatt et al.
5,376,380 A	12/1994	Kikuchi et al.
5,405,598 A	4/1995	Schinazi et al.
5,411,947 A	5/1995	Hostetler et al.
5,420,266 A	5/1995	Britton et al.
5,426,183 A	6/1995	Kjell
5,453,499 A	9/1995	Chou et al.
5,462,724 A	10/1995	Schinazi et al.
5,463,092 A	10/1995	Hostetler et al.
5,496,546 A	3/1996	Wang et al.
5,538,865 A	7/1996	Reyes et al.
5,543,389 A	8/1996	Yatvin et al.
5,543,390 A	8/1996	Yatvin et al.
5,543,391 A	8/1996	Yatvin et al.
5,554,728 A	9/1996	Basava et al.
5,610,054 A	3/1997	Draper
5,633,358 A	5/1997	Gruetzke et al.
5,633,388 A	5/1997	Diana et al.
5,676,942 A	10/1997	Testa et al.
5,703,058 A	12/1997	Schinazi et al.
5,711,944 A	1/1998	Gilbert et al.
5,725,859 A	3/1998	Omer
5,738,845 A	4/1998	Imakawa
5,738,846 A	4/1998	Greenwald et al.
5,747,646 A	5/1998	Hakimi et al.
5,767,097 A	6/1998	Tam
5,792,834 A	8/1998	Hakimi et al.
5,830,455 A	11/1998	Valtuna et al.
5,830,905 A	11/1998	Diana et al.
5,834,594 A	11/1998	Hakimi et al.

(Continued)

**Related U.S. Application Data**

- (62) Division of application No. 12/783,680, filed on May 20, 2010.
- (60) Provisional application No. 61/319,513, filed on Mar. 31, 2010, provisional application No. 61/179,923, filed on May 20, 2009.

- (51) **Int. Cl.**  
**A61K 31/7072** (2006.01)  
**A61K 31/664** (2006.01)  
**C07H 19/10** (2006.01)
- (52) **U.S. Cl.**  
CPC ..... **C07H 19/10** (2013.01); **A61K 31/7072** (2013.01); **A61K 31/664** (2013.01)  
USPC ..... **536/28.53**; 514/51
- (58) **Field of Classification Search**  
None  
See application file for complete search history.

**References Cited**

**U.S. PATENT DOCUMENTS**

3,798,209 A	3/1974	Witkowski et al.
3,852,267 A	12/1974	Meyer, Jr. et al.
RE29,835 E	11/1978	Witkowski et al.
4,814,477 A	3/1989	Wijnberg et al.
4,957,924 A	9/1990	Beauchamp
5,026,687 A	6/1991	Yarchoan et al.
5,118,820 A	6/1992	Hertel
5,149,794 A	9/1992	Yatvin et al.
5,157,027 A	10/1992	Biller et al.

**FOREIGN PATENT DOCUMENTS**

CA	2 682 230 A1	10/2008
CN	101108870 A	1/2008

(Continued)

**OTHER PUBLICATIONS**

U.S. Appl. No. 13/925,078, filed Jun. 2013, Ross et al.\*  
 Mitchell et al., "Bioreversible Protection for the Phospho Group: Bioactivation of the Di(4-acyloxybenzyl) and Mono(4-acyloxybenzyl) Phosphoesters of Methylphosphonate and Phosphonoacetate," J. Chem. Soc. Perkin. Trans. 1, pp. 2345-2353 (1992).  
 Olsen et al., "2'-Modified Nucleoside Analogs as Inhibitors of Hepatitis C RNA Replication," Program and Abstracts, 16th International Conference on Antiviral Research, Abstract No. 121, p. A76 (Apr. 27-May 1, 2003).  
 Otto, M., "Evaluation of Nucleoside Analogs in the Hepatitis C Virus Replicon System," Framing the Knowledge of Therapeutics for Viral Hepatitis, IHL Press, First Edition, pp. 247-261 (2006).

(Continued)

*Primary Examiner* — Eric S Olson  
 (74) *Attorney, Agent, or Firm* — Fitzpatrick, Cella, Harper & Scinto

(57) **ABSTRACT**

Disclosed herein are nucleoside phosphoramidates and their use as agents for treating viral diseases. These compounds are inhibitors of RNA-dependent 5 RNA viral replication and are useful as inhibitors of HCV NSSB polymerase, as inhibitors of HCV replication and for treatment of hepatitis C infection in mammals.

(56)

## References Cited

## U.S. PATENT DOCUMENTS

5,837,257	A	11/1998	Tsai et al.	7,429,572	B2	9/2008	Clark
5,846,964	A	12/1998	Ozeki	7,601,820	B2	10/2009	Wang et al.
5,849,696	A	12/1998	Chretien et al.	7,608,597	B2	10/2009	Sommadossi et al.
5,869,253	A	2/1999	Draper	7,608,600	B2	10/2009	Storer et al.
5,891,874	A	4/1999	Colacino et al.	7,635,689	B2	12/2009	LaColla et al.
5,905,070	A	5/1999	Schinazi et al.	7,879,815	B2	2/2011	MacCoss et al.
5,908,621	A	6/1999	Glue et al.	7,964,580	B2	6/2011	Sofia et al.
5,922,757	A	7/1999	Chojkier	8,173,621	B2	5/2012	Du et al.
5,928,636	A	7/1999	Alber et al.	8,334,270	B2	12/2012	Sofia et al.
5,942,223	A	8/1999	Bazer et al.	2001/0034440	A1	10/2001	Shepard et al.
5,980,884	A	11/1999	Blatt et al.	2002/0058635	A1	5/2002	Averett
5,990,276	A	11/1999	Zhang et al.	2002/0198173	A1	12/2002	Schinazi et al.
6,004,933	A	12/1999	Spruce et al.	2003/0050229	A1	3/2003	Sommadossi et al.
6,034,134	A	3/2000	Gold et al.	2003/0060400	A1	3/2003	LaColla et al.
6,043,077	A	3/2000	Barber et al.	2003/0120071	A1	6/2003	McGuigan et al.
6,056,961	A	5/2000	Lavie et al.	2003/0144502	A1	7/2003	Pietrzkowski et al.
6,060,080	A	5/2000	Kikuchi et al.	2003/0153744	A1	8/2003	Mekouar et al.
6,090,932	A	7/2000	McGee et al.	2003/0187018	A1	10/2003	Llinas-Brunet et al.
6,130,326	A	10/2000	Ramasamy et al.	2004/0006007	A1	1/2004	Gosselin et al.
6,132,763	A	10/2000	Fisher	2004/0014108	A1	1/2004	Eldrup et al.
6,156,501	A	12/2000	McGall et al.	2004/0023240	A1	2/2004	Marliere et al.
6,180,134	B1	1/2001	Zalipsky et al.	2004/0023901	A1	2/2004	Cook et al.
6,232,300	B1	5/2001	Schinazi et al.	2004/0059104	A1	3/2004	Cook et al.
6,239,159	B1	5/2001	Brown et al.	2004/0063622	A1	4/2004	Sommadossi et al.
6,348,587	B1	2/2002	Schinazi et al.	2004/0067901	A1	4/2004	Bhat et al.
6,372,883	B1	4/2002	Attwood et al.	2004/0072788	A1	4/2004	Bhat et al.
6,391,859	B1	5/2002	Schinazi et al.	2004/0097461	A1	5/2004	Sommadossi et al.
6,410,531	B1	6/2002	Llinas-Brunet et al.	2004/0097462	A1	5/2004	Sommadossi et al.
6,420,380	B2	7/2002	Llinas-Brunet et al.	2004/0101535	A1	5/2004	Sommadossi et al.
6,455,513	B1	9/2002	McGuigan et al.	2004/0102414	A1	5/2004	Sommadossi et al.
6,455,690	B1	9/2002	Tam et al.	2004/0110717	A1	6/2004	Carroll et al.
6,475,985	B1	11/2002	Wagner et al.	2004/0167140	A1	8/2004	Schinazi et al.
6,479,463	B1	11/2002	Wang et al.	2004/0191824	A1	9/2004	Dempcy et al.
6,495,677	B1	12/2002	Ramasamy et al.	2004/0214844	A1	10/2004	Otto et al.
6,509,320	B1	1/2003	Wang et al.	2004/0229839	A1	11/2004	Babu et al.
6,534,523	B1	3/2003	Bailey et al.	2004/0229840	A1	11/2004	Bhat et al.
6,552,183	B1	4/2003	Ramasamy et al.	2004/0248892	A1	12/2004	Wang
6,555,677	B2	4/2003	Petrillo et al.	2004/0254141	A1	12/2004	Schinazi et al.
6,573,248	B2	6/2003	Ramasamy et al.	2004/0259934	A1	12/2004	Olsen et al.
6,642,206	B2	11/2003	Ramasamy et al.	2004/0265969	A1	12/2004	Li et al.
6,660,721	B2	12/2003	Devos et al.	2004/0266996	A1	12/2004	Rabi
6,677,314	B2	1/2004	Kleckler et al.	2005/0009737	A1	1/2005	Clark
6,677,315	B2	1/2004	Kleckler et al.	2005/0020825	A1	1/2005	Storer et al.
6,680,303	B2	1/2004	Schinazi et al.	2005/0026853	A1	2/2005	Mekouar et al.
6,682,715	B2	1/2004	Kleckler et al.	2005/0031588	A1	2/2005	Sommadossi et al.
6,683,045	B2	1/2004	Kleckler et al.	2005/0075309	A1	4/2005	Storer et al.
6,703,374	B1	3/2004	Katki et al.	2005/0080034	A1	4/2005	Standing et al.
6,753,309	B2	6/2004	Kleckler et al.	2005/0090660	A1	4/2005	Watanabe et al.
6,777,395	B2	8/2004	Bhat et al.	2005/0124532	A1	6/2005	Sommadossi et al.
6,784,166	B2	8/2004	Devos et al.	2005/0130931	A1	6/2005	Boyer et al.
6,787,305	B1	9/2004	Li et al.	2005/0137161	A1	6/2005	Sommadossi et al.
6,787,526	B1	9/2004	Bryant et al.	2005/0148534	A1	7/2005	Castellino et al.
6,812,219	B2	11/2004	LaColla et al.	2005/0154056	A1	7/2005	Yang et al.
6,815,542	B2	11/2004	Hong et al.	2005/0164960	A1	7/2005	Olsen et al.
6,846,810	B2	1/2005	Martin et al.	2005/0215513	A1	9/2005	Boojamra et al.
6,897,201	B2	5/2005	Boyer et al.	2005/0227947	A1	10/2005	Chen et al.
6,908,924	B2	6/2005	Watanabe et al.	2005/0261237	A1	11/2005	Boojamra et al.
6,911,424	B2	6/2005	Schinazi et al.	2005/0267018	A1	12/2005	Blatt et al.
6,914,054	B2	7/2005	Sommadossi et al.	2006/0003951	A1	1/2006	Mekouar et al.
6,962,991	B2	11/2005	Dempcy et al.	2006/0033951	A1	1/2006	Dempcy et al.
7,018,985	B1	3/2006	Boyer et al.	2006/0014943	A1	1/2006	Dempcy et al.
7,018,989	B2	3/2006	McGuigan et al.	2006/0035866	A1	2/2006	Cannizzaro et al.
7,081,449	B2	7/2006	Pietrzkowski et al.	2006/0040890	A1	2/2006	Martin et al.
7,105,493	B2	9/2006	Sommadossi et al.	2006/0040927	A1	2/2006	Blake et al.
7,105,499	B2	9/2006	Carroll et al.	2006/0040944	A1	2/2006	Gosselin et al.
7,125,855	B2	10/2006	Bhat et al.	2006/0079478	A1	4/2006	Boojamra et al.
7,148,206	B2	12/2006	Sommadossi et al.	2006/0110727	A9	5/2006	McGall et al.
7,163,929	B2	1/2007	Sommadossi et al.	2006/0122146	A1	6/2006	Chun et al.
7,202,224	B2	4/2007	Eldrup et al.	2006/0122154	A1	6/2006	Olsen et al.
7,217,523	B2	5/2007	Wagner	2006/0142238	A1	6/2006	McGuigan
7,268,119	B2	9/2007	Cook et al.	2006/0166964	A1	7/2006	Hudyma et al.
7,307,065	B2	12/2007	Schinazi et al.	2006/0194749	A1	8/2006	Keicher et al.
7,323,453	B2	1/2008	Olsen et al.	2006/0199783	A1	9/2006	Wang et al.
				2006/0241064	A1	10/2006	Roberts et al.
				2006/0276511	A1	12/2006	Serrano-Wu et al.
				2006/0293306	A1	12/2006	Beaulieu et al.
				2007/0015905	A1	1/2007	LaColla et al.
				2007/0037735	A1	2/2007	Gosselin et al.

(56)

References Cited

U.S. PATENT DOCUMENTS

2007/0042988	A1	2/2007	Klumpp et al.	
2007/0042990	A1	2/2007	Gosselin et al.	
2007/0049754	A1	3/2007	Boojamra et al.	
2007/0060498	A1	3/2007	Gosselin et al.	
2007/0060541	A1	3/2007	Gosselin et al.	
2007/0087960	A1	4/2007	Storer et al.	
2007/0197463	A1	8/2007	Chun et al.	
2007/0225249	A1	9/2007	Shi	
2007/0265222	A1	11/2007	MacCoss et al.	
2007/0275912	A1	11/2007	Bhat et al.	
2007/0275947	A1	11/2007	Bergstrom	
2009/0137521	A1	5/2009	Hamilton et al.	
2009/0176732	A1	7/2009	Beigelman et al.	
2009/0233879	A1	9/2009	Reddy et al.	
2009/0280084	A1	11/2009	Schinazi et al.	
2009/0306007	A1	12/2009	Wagner	
2010/0016251	A1	1/2010	Sofia et al.	
2010/0022468	A1	1/2010	Meppen et al.	
2010/0029008	A1	2/2010	Rojas Stutz et al.	
2010/0035835	A1	2/2010	Narjes et al.	
2010/0081628	A1	4/2010	Du et al.	
2010/0137576	A1	6/2010	Stec et al.	
2010/0152128	A1	6/2010	Attenni et al.	
2010/0173863	A1	7/2010	Schinazi et al.	
2010/0227801	A1	9/2010	Hopkins	
2010/0279973	A1	11/2010	Chun et al.	
2010/0286083	A1	11/2010	Bao et al.	
2010/0298257	A1	11/2010	Ross et al.	
2010/0316594	A1	12/2010	Sommadossi et al.	
2011/0015146	A1	1/2011	Sofia et al.	
2011/0124592	A1	5/2011	Mcguigan et al.	
2011/0245484	A1	10/2011	Ross et al.	
2011/0251152	A1*	10/2011	Ross et al. .... 514/51	
2011/0257122	A1	10/2011	Sofia et al.	
2012/0107278	A1	5/2012	Berrey et al.	

FOREIGN PATENT DOCUMENTS

DE	199 14 474	A1	10/1999	
EP	0 180 276	A1	5/1986	
EP	0 350 287	A2	1/1990	
EP	1 828 217	A2	9/2007	
EP	1 881 001	A1	1/2008	
EP	2 097 430	A1	9/2009	
EP	2 124 555	A2	12/2009	
EP	2 207 786	B1	3/2012	
JP	5-238939	A	9/1993	
WO	89/02733	A1	4/1989	
WO	90/00555	A1	1/1990	
WO	91/16920	A1	11/1991	
WO	91/18914	A1	12/1991	
WO	91/19721	A1	12/1991	
WO	93/00910	A1	1/1993	
WO	94/26273	A1	11/1994	
WO	95/13090	A1	5/1995	
WO	95/24185	A1	9/1995	
WO	96/15132	A1	5/1996	
WO	96/32403	A2	10/1996	
WO	97/12033	A1	4/1997	
WO	97/36554	A1	10/1997	
WO	98/16184	A2	4/1998	
WO	98/17679	A1	4/1998	
WO	98/22496	A2	5/1998	
WO	99/07734	A2	2/1999	
WO	99/15194	A1	4/1999	
WO	99/32139	A1	7/1999	
WO	99/32140	A1	7/1999	
WO	99/43691	A1	9/1999	
WO	99/59621	A1	11/1999	
WO	99/64016	A1	12/1999	
WO	00/06529	A1	2/2000	
WO	00/09531	A2	2/2000	

WO	01/32153	A2	5/2001	
WO	01/60315	A2	8/2001	
WO	01/79246	A2	10/2001	
WO	01/81359	A1	11/2001	
WO	01/90121	A2	11/2001	
WO	01/91737	A2	12/2001	
WO	01/92282	A2	12/2001	
WO	01/96353	A2	12/2001	
WO	02/08187	A1	1/2002	
WO	02/08198	A2	1/2002	
WO	02/08251	A2	1/2002	
WO	02/08256	A2	1/2002	
WO	02/18404	A2	3/2002	
WO	02/32414	A2	4/2002	
WO	02/32920	A2	4/2002	
WO	02/48116	A2	6/2002	
WO	02/48157	A2	6/2002	
WO	02/48165	A2	6/2002	
WO	02/48172	A2	6/2002	
WO	02/057287	A2	7/2002	
WO	02/057425	A2	7/2002	
WO	02/060926	A2	8/2002	
WO	02/100415	A2	12/2002	
WO	03/000713	A1	1/2003	
WO	03/006490	A1	1/2003	
WO	03/010141	A2	2/2003	
WO	03/024461	A1	3/2003	
WO	03/026589	A2	4/2003	
WO	03/037895	A1	5/2003	
WO	03/051899	A1	6/2003	
WO	03/053989	A1	7/2003	
WO	03/061576	A2	7/2003	
WO	03/062256	A1	7/2003	
WO	03/064456	A1	8/2003	
WO	03/068244	A1	8/2003	
WO	03/101993	A1	12/2003	
WO	03/104250	A1	12/2003	
WO	03/105770	A2	12/2003	
WO	03/106477	A1	12/2003	
WO	04/000858	A2	12/2003	
WO	2004/002422	A2	1/2004	
WO	2004/002940	A1	1/2004	
WO	2004/002944	A1	1/2004	
WO	2004/002977	A1	1/2004	
WO	2004/002999	A2	1/2004	
WO	2004/003000	A2	1/2004	
WO	2004/003138	A2	1/2004	
WO	2004/007512	A2	1/2004	
WO	2004/009020	A2	1/2004	
WO	2004/009610	A2	1/2004	
WO	2004/011478	A2	2/2004	
WO	2004/014313	A2	2/2004	
WO	2004/014852	A2	2/2004	
WO	2004/035571	A1	4/2004	
WO	2004/041201	A2	5/2004	
WO	2004/046331	A2	6/2004	
WO	2004/065367	A1	8/2004	
WO	2004/080466	A1	9/2004	
WO	2004/094452	A2	11/2004	
WO	2004/096210	A1	11/2004	
WO	2004/096234	A2	11/2004	
WO	2004/096235	A2	11/2004	
WO	2004/096286	A2	11/2004	
WO	2004/106356	A1	12/2004	
WO	2005/002626	A2	1/2005	
WO	2005/003147	A2	1/2005	
WO	2005/007810	A2	1/2005	
WO	2005/009418	A2	2/2005	
WO	2005/012327	A2	2/2005	
WO	2005/020884	A2	3/2005	
WO	2005/021568	A2	3/2005	
WO	2005/028502	A1	3/2005	
WO	2005/037214	A2	4/2005	
WO	2005/067900	A2	7/2005	
WO	2005/072361	A2	8/2005	
WO	2005/082144	A1	9/2005	
WO	2005/087788	A2	9/2005	

(56)

## References Cited

## FOREIGN PATENT DOCUMENTS

WO	2005/123087	A2	12/2005
WO	2006/000922	A2	1/2006
WO	2006/012078	A2	2/2006
WO	2006/012440	A2	2/2006
WO	2006/020082	A1	2/2006
WO	2006/029081	A2	3/2006
WO	2006/031725	A2	3/2006
WO	2006/035061	A1	4/2006
WO	2006/037028	A2	4/2006
WO	2006/050161	A2	5/2006
WO	2006/063149	A1	6/2006
WO	2006/063717	A2	6/2006
WO	2006/065335	A2	6/2006
WO	2006/065590	A2	6/2006
WO	2006/093801	A1	9/2006
WO	2006/100310	A1	9/2006
WO	2006/116557	A1	11/2006
WO	2006/120251	A1	11/2006
WO	2006/120252	A2	11/2006
WO	2006/121820	A1	11/2006
WO	2007/002602	A2	1/2007
WO	2007/014920	A1	2/2007
WO	2007/014921	A1	2/2007
WO	2007/014922	A1	2/2007
WO	2007/014925	A1	2/2007
WO	2007/014926	A1	2/2007
WO	2007/015824	A2	2/2007
WO	2007/020193	A2	2/2007
WO	2007/027248	A2	3/2007
WO	2007/039142	A1	4/2007
WO	2007/039145	A1	4/2007
WO	2007/065829	A1	6/2007
WO	2007/070556	A2	6/2007
WO	2007/076034	A2	7/2007
WO	2007/088148	A1	8/2007
WO	2007/092000	A1	8/2007
WO	2007/093901	A1	8/2007
WO	2007/095269	A2	8/2007
WO	2008/010921	A2	1/2008
WO	2008/045419	A1	4/2008
WO	2008/048128	A1	4/2008
WO	2008/062206	A2	5/2008
WO	2008/079206	A1	7/2008
WO	2008/082601	A2	7/2008
WO	2008/085508	A2	7/2008
WO	2008121634	A1	9/2008
WO	2008/142055	A2	11/2008
WO	2009/029844	A1	3/2009
WO	2009/052287	A1	4/2009
WO	2009/115893	A2	9/2009
WO	2009/120878	A2	10/2009
WO	2009/129120	A2	10/2009
WO	2009/132123	A1	10/2009
WO	2009/152095	A2	12/2009
WO	2010/042834	A1	4/2010
WO	2010/075517	A2	7/2010
WO	2010/075549	A2	7/2010
WO	2010/075554	A1	7/2010
WO	2010/080878	A1	7/2010
WO	2010/081082	A2	7/2010
WO	2011/035231	A1	3/2011

## OTHER PUBLICATIONS

Piantadosi et al., "Synthesis and Evaluation of Novel Ether Lipid Nucleoside Conjugates for Anti-HIV-1 Activity," *J. Med. Chem.*, vol. 34, No. 4, pp. 1408-1414 (1991).

Pierra et al., "Synthesis and Pharmacokinetics of Valopicitabine (NM283), an Efficient Prodrug of the Potent Anti-HCV Agent 2'-C-Methylcytidine," *J. Med. Chem.*, vol. 49, No. 22, pp. 6614-6620 (2006).

Starrett, Jr. et al., "Synthesis, Oral Bioavailability Determination, and in Vitro Evaluation of Prodrugs of the Antiviral Agent 9-[2-

Stuyver et al., "Inhibition of hepatitis C replicon RNA synthesis by B-D-2'-deoxy-2'-fluoro-2'-C-methylcytidine: a specific inhibitor of hepatitis C virus replication," *Antiviral Chemistry & Chemotherapy*, vol. 17, No. 2, pp. 79-87 (2006).

Stuyver et al., "Dynamics of Subgenomic Hepatitis C Virus Replicon RNA Levels in Huh-7 Cells after Exposure to Nucleoside Antimetabolites," *J. Virol.*, vol. 77, No. 19, pp. 10689-10694 (2003).

Stuyver et al., "Ribonucleoside Analogue that Blocks Replication of Bovine Viral Diarrhea and Hepatitis C Viruses in Culture," *Antimicrobial Agents and Chemotherapy*, vol. 47, No. 1, pp. 244-254 (2003).

Wolff, M.E., "Burger's Medicinal Chemistry and Drug Discovery," Fifth Edition, vol. 1, pp. 975-977 (1995).

Zon, G., "4 Cyclophosphamide Analogues," *Progress in Medicinal Chemistry*, vol. 19, pp. 205-246 (1982).

Bhat et al., "Synthesis and Pharmacokinetic Properties of Nucleoside Analogues as Possible Inhibitors of HCV RNA Replication," (Oral Session V: Hepatitis C Virus, Flaviviruses), 16th International Conference on Antiviral Research, Abstract No. 120, p. A75 (Apr. 27-May 1, 2003).

Chu et al., "Isolation and Structure of SCH 351633: A Novel Hepatitis C Virus (HCV) NS3 Protease Inhibitor from the Fungus *Penicillium Griseofulvum*," *Bioorg. & Med. Chem. Lett.*, vol. 9, pp. 1949-1952 (1999).

Chu et al., "Structure of Sch 68631: A New Hepatitis C Virus Proteinase Inhibitor from *Streptomyces* sp." *Tet. Lett.*, vol. 37, No. 40, pp. 7229-7232 (1996).

De Lombaert et al., "N-Phosphonomethyl Dipeptides and Their Phosphonate Prodrugs, a New Generation of Neutral Endopeptidase (NEP, EC 3.4.24.11) Inhibitors," *J. Med. Chem.*, vol. 37, No. 4, pp. 498-511 (1994).

Edmundson et al., "Cyclic Organophosphorus Compounds. Part 23. Configurational Assignments in the 4-Phenyl-1,3,2-dioxaphosphorinane Series. X-Ray Molecular Structure of cis-2-Benzylamino-4-phenyl-1,3,2-dioxaphosphorinane 2-oxide," *J. Chem. Research (S)*, pp. 122-123 (1989).

Goekjian et al., "Synthesis of Fluorinated Marcocyclic Bis(indolyl)maleimides as Potential 19F NMR Probes for Protein Kinase C," *J. Org. Chem.*, vol. 64, No. 12, pp. 4238-4246 (1999).

Hernandez et al., "Synthesis of Highly Functionalized Chiral Nitriles by Radical Fragmentation of beta-Hydroxy Azides. Convenient Transformation of Aldonitriles into 1,4- and 1,5-Iminoalditols," *J. Org. Chem.*, vol. 69, No. 24, pp. 8437-8444 (2004).

Hostetler et al., "Greatly Enhanced Inhibition of Human Immunodeficiency Virus Type 1 Replication in CEM and HT4-6C Cells by 3'-Deoxythymidine Diphosphate Dimyristoylglycerol, a Lipid Prodrug of 3'-Deoxythymidine," *Antimicrobial Agents and Chemotherapy*, vol. 36, No. 9, pp. 2025-2029 (1992).

Kucera et al., "Novel Membrane-Interactive Ether Lipid Analogs That Inhibit Infectious HIV-1 Production and Induce Defective Virus Formation," *Aids Research and Human Retroviruses*, vol. 6, No. 4, pp. 491-501 (1990).

Meier et al., "Cyclic Saligenyl Phosphotriesters of 2',3'-Dideoxy-2',3'-dideoxythymidine (d4T)—A New Pro-Nucleotide Approach," *Bioorg. & Med. Chem. Lett.*, vol. 7, No. 2, pp. 99-104, (1997).

Neidlein et al., "Mild Preparation of 1-Benzoyloxyiminoalkylphosphonic Dichlorides: Application to the Synthesis of Cyclic Phosphonic Diesters and Cyclic Monoester Amides," *Heterocycles*, vol. 35, No. 2, pp. 1185-1203 (1993).

Nifant'ev et al., "Synthesis and Structure of Some Stable Phospholane-Phospholanes," *Phosphorus, Sulfur, and Silicon*, vol. 113, pp. 1-13 (1996).

Novak, J. J. K., "Chiroptical Properties of 2-Methyl-1,4-Lactones; Revised Absolute Configuration of 2-Deoxy-2-C-Methyl-erythro-D-Pentono-1,4-Lactones," *Collection Czechoslov. Chem. Commun.*, vol. 39, pp. 869-882 (1974).

Novak, J. J. K., "Nucleic Acid Components and Their Analogues CXLI. Nucleosides Derived from 2-Deoxy-2(R)-C-Methyl-

(56)

## References Cited

## OTHER PUBLICATIONS

- Oishi et al., "Asymmetric Dihydroxylation of Chiral Olefins. High Control of Diastereofacial Selection," *Tet. Lett.*, vol. 34, No. 22, pp. 3573-3576 (1993).
- Shih et al., "Preparation and Structures of 2-Dimethylamino-4-phenyl-1,3,2-dioxaphosphorinane-2-oxides," *Bull. Inst. Chem., Acad. Sin.*, vol. 41, pp. 9-16, (Mar. 1994).
- Stella, V. J., "Prodrugs as Therapeutics," Expert opinion on therapeutic patents, vol. 14, No. 3, pp. 277-280 (Mar. 2004).
- Xiao-Ling et al., "Study on the Chirality of Sulfur in Ethyl (2S,3R,4R)-4,5-O-Isopropylidene-2,3-sulfinyl-2,3,4,5-tetrahydroxypentanoate," *Acta Chimica Sinica*, vol. 55, pp. 600-604 (1997).
- Xiao-Ling et al., "The Synthesis of (2S,3R)-Sphingosine from D-Mannitol," *Acta Chimica Sinica*, vol. 54, pp. 826-832 (1996).
- International Search Report issued in International Application No. PCT/US2004/012472 mailed Dec. 30, 2004 (4 pages).
- International Search Report issued in International Application No. PCT/US2005/025916 mailed Jun. 15, 2006 (2 pages).
- International Search Report issued in International Application No. PCT/EP2006/069060 mailed Jan. 30, 2007 (4 pages).
- International Search Report issued in International Application No. PCT/US2005/032406 mailed May 8, 2008 (3 pages).
- Bartenschlager et al., "Nonstructural Protein 3 of the Hepatitis C Virus Encodes a Serine-Type Proteinase Required for Cleavage at the NS3/4 and NS4/5 Junctions," *J. Virol.*, vol. 67, No. 7, pp. 3835-3844 (1993).
- Bartenschlager et al., "Kinetic and Structural Analyses of Hepatitis C Virus Polyprotein Processing," *J. Virol.*, vol. 68, No. 8, pp. 5045-5055 (1994).
- Bazan et al., "Detection of a Trypsin-like Serine Protease Domain in Flaviviruses and Pestiviruses," *Virology*, vol. 171, pp. 637-639 (1989).
- Beaulieu et al., "Inhibitors of the HCV NS5B polymerase: New hope for the treatment of hepatitis C infections," *Current Opinion in Investigational Drugs*, vol. 5, No. 8, pp. 838-850 (2004).
- Behrens et al., "Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus," *The EMBO Journal*, vol. 15, No. 1, pp. 12-22 (1996).
- Calisher et al., "Antigenic Relationships between Flaviviruses as Determined by Cross-neutralization Tests with Polyclonal Antisera," *J. Gen. Virol.*, vol. 70, pp. 37-43 (1989).
- Carroll et al., "Nucleoside Analog Inhibitors of Hepatitis C Virus Replication," *Infectious Disorders—Drug Targets*, vol. 6, No. 1, pp. 17-29 (2006).
- Eckart et al., "The Hepatitis C Virus Encodes a Serine Protease Involved in Processing of the Putative Nonstructural Proteins from the Viral Polyprotein Precursor," *Biochemical and Biophysical Research Communications*, vol. 192, No. 2, pp. 399-406 (1993).
- Failla et al., "Both NS3 and NS4A are Required for Proteolytic Processing of Hepatitis C Virus Nonstructural Proteins," *J. Virol.*, vol. 68, No. 6, pp. 3753-3760 (1994).
- Rice, C. M., "Flaviviridae: The Viruses and Their Replication," *Fields Virology*, 3rd Edition, vol. 1, pp. 931-959 (1996).
- Gorbalenya et al., "A conserved NTP-motif in putative helicases," *Nature*, vol. 333, p. 22 (1988).
- Gorbalenya et al., "N-terminal domains of putative helicases of flaviviruses and pestiviruses may be serine proteases," *Nucleic Acids Research*, vol. 17, No. 10, pp. 3889-3897 (1989).
- Grakoui et al., "Characterization of the Hepatitis C Virus-Encoded Serine Proteinase: Determination of Proteinase-Dependent Polyprotein Cleavage Sites," *J. Virol.*, vol. 67, No. 5, pp. 2832-2843 (1993).
- Grakoui et al., "A second hepatitis C virus-encoded proteinase," *Proc. Natl. Acad. Sci.*, vol. 90, pp. 10583-10587 (1993).
- Griffith et al., "HCV Anti-viral Agents," *Annual Reports in Medicinal Chemistry*, vol. 39, pp. 223-237 (2004).
- Halstead, S. B., "Selective Primary Health Care: Strategies for Con-
- Murakami, E., et al., "The Mechanism of Action of beta-D-2'-Deoxy-2'-fluoro-2'-C-methylcytidine Involves a Second Metabolic Pathway Leading to beta-D-2'-Deoxy-2'-fluoro-2'-C-methyluridine 5'-Triphosphate, a Potent Inhibitor of the HCV RNA-Dependent RNA Polymerase," 14th International Symposium on Hepatitis C Virus and Related Viruses, Glasgow, Scotland (Sep. 2007).
- Halstead, S. B., "Pathogenesis of Dengue: Challenges to Molecular Biology," *Science*, vol. 239, pp. 476-481 (1988).
- Hijikata et al., "Two Distinct Proteinase Activities required for the Processing of a Putative Nonstructural Precursor Protein of Hepatitis C Virus," *J. Virol.*, vol. 67, No. 8, pp. 4665-4675 (1993).
- Jin et al., "Expression, Isolation, and characterization of the Hepatitis C Virus ATPase/RNA Helicase," *Archives of Biochemistry and Biophysics*, vol. 323, No. 1, pp. 47-53 (1995).
- Kim et al., "C-Terminal Domain of the Hepatitis C Virus NS3 Protein Contains an RNA Helicase Activity," *Biochemical and Biophysical Research Communications*, vol. 215, No. 1, pp. 160-166 (1995).
- Koonin et al., "Evolution and Taxonomy of Positive-Strand RNA Viruses: Implications of Comparative Analysis of Amino Acid Sequences," *Critical Reviews in Biochemistry and Molecular Biology*, vol. 28, No. 5, pp. 375-430 (1993).
- Lohmann et al., "Biochemical Properties of Hepatitis C Virus NS5B RNA-Dependent RNA Polymerase and Identification of Amino Acid Sequence Motifs Essential for Enzymatic Activity," *J. Virol.*, vol. 71, No. 11, pp. 8416-8428 (1997).
- Meyers et al., "Molecular Characterization of Pestiviruses," *Advance in Virus Research*, vol. 47, pp. 53-119 (1996).
- Moennig et al., "The Pestiviruses," *Advances in Virus Research*, vol. 41, pp. 53-99 (1992).
- Monath, T. P., M.D., "Japanese Encephalitis—A Plague of the Orient," *N. Engl. J. Med.*, vol. 319, No. 10, pp. 641-643 (Sep. 8, 1988).
- Ni et al., "Progress and development of small molecule HCV antivirals," *Current Opinion in Drug Discovery & Development*, vol. 7, No. 4, pp. 446-459 (2004).
- Tan et al., "Hepatitis C Therapeutics: current Status and Emerging Strategies," *Nature Reviews*, vol. 1, pp. 867-881 (2002).
- Tomei et al., "NS3 Is a Serine Protease Required for Processing of Hepatitis C Virus Polyprotein," *J. Virol.*, vol. 67, No. 7, pp. 4017-4026 (1993).
- Walker et al., "Promising candidates for the treatment of chronic hepatitis C," *Expert Opin. Investig. Drugs*, vol. 12, No. 8, pp. 1269-1280 (2003).
- Warrener et al., "Pestivirus NS3 (p80) Protein Possesses RNA Helicase Activity," *J. Virol.*, vol. 69, No. 3, pp. 1720-1726 (1995).
- Wiskerchen et al., "Pestivirus Gene Expression: Protein p80 of Bovine Viral Diarrhea Virus Is a Proteinase Involved in Polyprotein Processing," *Virology*, vol. 184, pp. 341-350 (1991).
- Wu et al., "Targeting NS5B RNA-Dependent RNA Polymerase for Anti-HCV Chemotherapy," *Current Drug Targets—Infectious Disorders*, vol. 3, No. 3, pp. 207-219 (2003).
- Xu et al., "Bovine Viral Diarrhea Virus NS3 Serine Proteinase: Polyprotein Cleavage Sites, Cofactor Requirements, and Molecular Model of an Enzyme Essential for Pestivirus Replication," *J. Virol.*, vol. 71, No. 7, pp. 5312-5322 (1997).
- Yuan et al., "Expression, Purification, and Partial Characterization of HCV RNA Polymerase," *Biochemical and Biophysical Research Communications*, vol. 232, No. 1, pp. 231-235 (1997).
- Zhong et al., "Identification and characterization of an RNA-Dependent RNA Polymerase Activity within the Nonstructural Protein 5B Region of Bovine Viral Diarrhea Virus," *J. Virol.*, vol. 72, No. 11, pp. 9365-9369 (1998).
- Aquaro et al., "Activities of Masked 2',3'-Dideoxynucleoside Monophosphate Derivatives Against Human Immunodeficiency Virus in Resting Macrophages," *Antimicrobial Agents and Chemotherapy*, vol. 44, No. 1, pp. 173-177 (2000).
- Chapman et al., "Purification of PMPA Amidate Prodrugs by SMB Chromatography and X-Ray Crystallography of the Diastereomerically Pure GS-7340," *Nucleosides, Nucleotides & Nucleic Acids*, vol. 20, No. 4-7, pp. 1085-1090 (2001).
- Chapman et al., "Practical Synthesis, Separation, and Stereochemical

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.